News & Analysis

Latest content

InterDigital announces Amazon deal and record non-smartphone income

The firm is the latest in a string of big-ticket licensors to have published their quarterly earnings, following Ericsson, Nokia and Qualcomm

05 August 2022

UK publishes SEP outreach responses, but no changes are imminent

Despite the increasing attraction of the London courts, the real FRAND focus in Europe is likely to be on EU action which is promised by the end of the year

05 August 2022

IP-backed lending is becoming a serious option for many companies

Utilising patents as collateral for credit can save expense or even provide capital when VC or traditional lenders refuse

05 August 2022

US judge rejects claims that EU data regulations required heavy redaction of documents in NPE patent case

Defendant Continental had argued that the GDPR meant it had to black out key information in a case brought by Arigna Technology against a group of OEMs

04 August 2022

Patent thickets not a problem, says US court in AbbVie case

The company’s controversial Humira IP strategy is not anticompetitive, says the Court of Appeals for the Seventh Circuit

04 August 2022

Quality patents matter most, but quantity helps you secure them

Value is in the eye of the beholder and depends on what a rights holder wants to do with its assets, senior portfolio managers say

04 August 2022

Tillis’s 101 reform bill wins plaudits despite flaws

The Patent Eligibility Restoration Act of 2022 effectively overturns Supreme Court precedent and provides greater clarity on eligibility but some believe it may require further work

03 August 2022

The contribution patents make to enterprise value

No commonly used valuation methods are much help at putting a number on an entire portfolio unless there is a specific transaction on the horizon. Cipher’s Nigel Swycher and Steve Harris suggest an original methodology to fill this gap

03 August 2022

Xifaxan patent loss causes Bausch shares to tumble

The invalidation of US rights underpinning the anti-intestinal-infection drug has shaken confidence in the company’s future

03 August 2022

Experts react to USPTO planned revision of section 101 guidance

While most observers welcome a revisit, many believe that only the Supreme Court or Congress can deliver significant levels of certainty on eligibility

02 August 2022

Get unlimited access to all IAM content